{
  "nctId": "NCT02794441",
  "briefTitle": "Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department",
  "officialTitle": "Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in Pediatric Patients Presenting to the Emergency Department With Migraine: A Pilot Randomized Controlled Trial",
  "protocolDocument": {
    "nctId": "NCT02794441",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2016-06-04",
    "uploadDate": "2018-04-30T10:48",
    "size": 1291040,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02794441/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 12,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-12",
    "completionDate": "2017-06-28",
    "primaryCompletionDate": "2017-06",
    "firstSubmitDate": "2016-05-25",
    "firstPostDate": "2016-06-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Between the ages of 8 and 18 years (ie. \\> 8.0 years and \\< 18.0 years)\n2. Diagnosed with migraine according to a modified version of International Classification of Headache Disorders 3rd edition (ICHD-3, beta version) where criterion A (ie. minimum of 5 prior episodes meeting criteria B-D) has been removed to increase sensitivity of diagnosis in the emergency department setting\n\nExclusion Criteria:\n\n1. Received a dose of a steroid medication in the past 7 days\n2. Known allergy to dexamethasone\n3. Immunosuppressed\n4. Cushing's syndrome\n5. Known diabetes mellitus\n6. Known peptic or duodenal ulcer or other major gastrointestinal illness (ex. ulcerative colitis)\n7. Known myasthenia gravis\n8. Glaucoma\n9. Febrile at triage\n10. History of head trauma in the past 7 days\n11. Presence of any known active infection (eg. on antibiotics or antivirals, diagnosed with active infection in the ED, etc)\n12. Current secondary headache (as per the treating physician's clinical impression)",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "8 Years",
    "maximumAge": "18 Years",
    "stdAges": [
      "CHILD",
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Headache Recurrence at 48 Hours",
        "description": "The primary outcome will be headache recurrence 48 hours after discharge from the ED. Headache recurrence will be defined as: for patients who were pain-free at ED discharge (ie. pain intensity of 0), any return of head pain (ie. pain intensity of 1 or greater) will be coded as a recurrence, and for patients who had persistent head pain at discharge, an increase in head pain since ED discharge will be coded as recurrence as well (ie. an increase in their score on the 4-point scale as compared to their score at ED discharge).",
        "timeFrame": "48 hours"
      }
    ],
    "secondary": [
      {
        "measure": "Pain Intensity",
        "description": "Pain intensity will be measured on a 4 point rating scale as recommended by the International Headache Society guidelines: a) 0=none, b) 1=mild, c) 2= moderate, d) 4=severe. It will be assessed at 2 hours post-baseline, or at the time of ED discharge if prior to 2 hours and at the time of ED discharge where this exceeds 2 hours post-intervention. Because all participants were discharged prior to 2 hours, we report the pain intensity at the time of ED discharge.",
        "timeFrame": "Baseline, 2 hours post-intervention (or at the time of ED discharge if prior to 2 hours) and at the time of discharge from the Emergency Department (ED) if post-treatment ED duration extends beyond 2 hours (expected median duration = 3 hours)"
      },
      {
        "measure": "Persistent Pain Freedom",
        "description": "Persistent pain freedom, defined as the proportion of patients in each group who achieved pain freedom at 2 hours (or at the time of ED discharge if prior to 2 hours) and were free of pain without the use of rescue medication at 48 hours, will be assessed",
        "timeFrame": "2 hours post-intervention (or at the time of ED discharge if prior to 2 hours) and 48 hours"
      },
      {
        "measure": "Patient Satisfaction",
        "description": "Patient satisfaction will be assessed at the time of discharge from the ED and again at follow-up with the following 5-point Likert scale: 5=very satisfied, 4=satisfied, 3=neutral, 2=unsatisfied, 1=very unsatisfied. Here we report patient satisfaction rates at discharge.",
        "timeFrame": "At the time of discharge from the ED (expected median duration in the ED post-treatment = 3 hours), at 48 hours and at 7 day follow-up"
      },
      {
        "measure": "Headache Recurrence at 7 Day Follow-up",
        "description": "The proportion of patients in each group with recurrence within the 7 days following ED discharge will be assessed.",
        "timeFrame": "7 days"
      },
      {
        "measure": "Revisits Within 7 Days of Discharge From the ED",
        "description": "The number of patients with return ED visits within 7 days of ED discharge will be assessed through chart review.",
        "timeFrame": "7 days"
      },
      {
        "measure": "Adverse Events at Discharge",
        "description": "Adverse events will be queried at 2 hours (or at the time of ED discharge if prior to 2 hours), at discharge and in the follow-up questionnaires at 48 hours and 7 days. Reported here are the adverse events at the time of ED discharge. All patients were discharged prior to the 2 hour time point. Adverse events reported at follow-up are reported elsewhere (see below).",
        "timeFrame": "2 hours post-intervention (or at the time of ED discharge if prior to 2 hours), at the time of discharge from the Emergency Department (ED) if post-treatment ED duration extends beyond 2 hours (expected median duration = 3 hours), 48 hours and 7 days"
      },
      {
        "measure": "Adverse Events at 48 Hours Post-discharge",
        "description": "Adverse events will be queried at 2 hours (or at the time of ED discharge if prior to 2 hours), at discharge and in the follow-up questionnaires at 48 hours and 7 days. Reported here are the adverse events at the 48 hour follow-up post-discharge.",
        "timeFrame": "2 hours post-intervention (or at the time of ED discharge if prior to 2 hours), at the time of discharge from the Emergency Department (ED) if post-treatment ED duration extends beyond 2 hours (expected median duration = 3 hours), 48 hours and 7 days"
      },
      {
        "measure": "Adverse Events at 7 Days Post-discharge",
        "description": "Adverse events will be queried at 2 hours (or at the time of ED discharge if prior to 2 hours), at discharge and in the follow-up questionnaires at 48 hours and 7 days. Reported here are the adverse events at the 7 day follow-up post-discharge.",
        "timeFrame": "2 hours post-intervention (or at the time of ED discharge if prior to 2 hours), at the time of discharge from the Emergency Department (ED) if post-treatment ED duration extends beyond 2 hours (expected median duration = 3 hours), 48 hours and 7 days"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 8,
      "otherCount": 0,
      "totalCount": 9
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 79,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:54.097Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}